Survival outcomes in trial defined high-risk hormone receptor-positive/human epidermal growth factor receptor II-negative early breast cancer: impact of adjuvant chemotherapy
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Adjuvant chemotherapy benefits high-risk early breast cancer patients. Further research is needed to tailor chemotherapy for specific patient groups receiving CDK4/6 inhibitors.
Area Of Science
- Oncology
- Clinical Research
- Breast Cancer Treatment
Background
- Hormone receptor-positive (HR+), HER2-negative early breast cancer is a significant clinical challenge.
- CDK4/6 inhibitors combined with endocrine therapy show efficacy in high-risk early breast cancer.
- Identifying optimal adjuvant treatment strategies remains crucial for improving patient outcomes.
Purpose Of The Study
- To evaluate the impact of adjuvant chemotherapy on overall survival (OS) and recurrence-free survival (RFS) in high-risk HR+/HER2- early breast cancer.
- To assess patient subgroups defined by MonarchE and NATALEE high-risk criteria.
- To inform personalized chemotherapy decisions in the context of CDK4/6 inhibitor use.
Main Methods
- Retrospective analysis of HR+/HER2- early breast cancer cases from a cancer registry.
- Stratification of patients based on MonarchE (M) and NATALEE (N) high-risk criteria.
- Primary endpoints included OS and RFS, with subgroup analyses for chemotherapy impact.
Main Results
- Among 2758 cases, 511 met MonarchE and 1207 met NATALEE high-risk criteria.
- Adjuvant chemotherapy significantly reduced recurrence risk in MonarchE high-risk patients (HR: 0.24).
- Chemotherapy showed no overall benefit for NATALEE high-risk patients, except for stage III cases (HR: 0.2).
Conclusions
- Adjuvant chemotherapy is beneficial for reducing recurrence in MonarchE high-risk early breast cancer.
- Further stratification of patients, particularly M-low/N-high, is necessary for tailored chemotherapy decisions.
- Optimizing adjuvant chemotherapy alongside CDK4/6 inhibitors requires refined patient selection criteria.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...